Biogen Inc. – ‘10-K’ for 12/31/23 – ‘XML’

On:  Tuesday, 2/13/24, at 5:40pm ET   ·   As of:  2/14/24   ·   For:  12/31/23   ·   Accession #:  875045-24-9   ·   File #:  0-19311

in

this entire Filing. an “Entity” Search.

Show

Documents searched

and

each “hit”. the 1st “hit”.

↓↑Hints

Annual Report   —   Form 10-K   —   SEA’34

Filing Table of Contents

Document/Exhibit                   Description                      Pages   Size 

 1: 10-K        Annual Report                                       HTML   4.17M 
 2: EX-4.6      Instrument Defining the Rights of Security Holders  HTML     47K 
 3: EX-10.32    Material Contract                                   HTML     48K 
 4: EX-10.33    Material Contract                                   HTML    172K 
 5: EX-10.35    Material Contract                                   HTML     71K 
 6: EX-21       Subsidiaries List                                   HTML     62K 
 7: EX-23       Consent of Expert or Counsel                        HTML     45K 
11: EX-97.1     Clawback Policy re: Recovery of Erroneously         HTML     58K 
                Awarded Compensation                                             
 8: EX-31.1     Certification -- §302 - SOA'02                      HTML     50K 
 9: EX-31.2     Certification -- §302 - SOA'02                      HTML     50K 
10: EX-32.1     Certification -- §906 - SOA'02                      HTML     48K 
17: R1          Cover Page                                          HTML    111K 
18: R2          Audit Information                                   HTML     50K 
19: R3          Consolidated Statements of Income                   HTML    143K 
20: R4          Consolidated Statements of Comprehensive Income     HTML     87K 
21: R5          Consolidated Balance Sheets                         HTML    180K 
22: R6          Consolidated Balance Sheets (Parenthetical)         HTML     53K 
23: R7          Consolidated Statements of Cash Flows               HTML    163K 
24: R8          Consolidated Statements of Equity                   HTML    149K 
25: R9          Summary of Significant Accounting Policies          HTML    149K 
26: R10         Acquisitions                                        HTML     99K 
27: R11         Dispositions                                        HTML     55K 
28: R12         Restructuring                                       HTML     88K 
29: R13         Revenue                                             HTML    221K 
30: R14         Inventory                                           HTML     63K 
31: R15         Intangible Assets and Goodwill                      HTML    102K 
32: R16         Fair Value Measurements                             HTML    141K 
33: R17         Financial Instruments                               HTML    117K 
34: R18         Derivative Instruments                              HTML    108K 
35: R19         Property, Plant and Equipment                       HTML     64K 
36: R20         Leases                                              HTML     95K 
37: R21         Indebtedness                                        HTML     86K 
38: R22         Equity                                              HTML    146K 
39: R23         Earnings per Share                                  HTML     64K 
40: R24         Share-Based Payments                                HTML    159K 
41: R25         Income Taxes                                        HTML    144K 
42: R26         Other Consolidated Financial Statement Detail       HTML     92K 
43: R27         Collaborative and Other Relationships               HTML    183K 
44: R28         Investments in Variable Interest Entities           HTML     55K 
45: R29         Litigation                                          HTML     62K 
46: R30         Commitments and Contingencies                       HTML     59K 
47: R31         Guarantees                                          HTML     51K 
48: R32         Employee Benefit Plans                              HTML     56K 
49: R33         Segment Information                                 HTML     99K 
50: R34         Pay vs Performance Disclosure                       HTML     57K 
51: R35         Insider Trading Arrangements                        HTML     68K 
52: R36         Summary of Significant Accounting Policies          HTML    216K 
                (Policies)                                                       
53: R37         Summary of Significant Accounting Policies          HTML     64K 
                (Tables)                                                         
54: R38         Acquisitions (Tables)                               HTML     84K 
55: R39         Restructuring (Tables)                              HTML     86K 
56: R40         Revenue (Tables)                                    HTML    230K 
57: R41         Inventory (Tables)                                  HTML     60K 
58: R42         Intangible Assets and Goodwill (Tables)             HTML     94K 
59: R43         Fair Value Measurements (Tables)                    HTML    134K 
60: R44         Financial Instruments (Tables)                      HTML    119K 
61: R45         Derivative Instruments (Tables)                     HTML    108K 
62: R46         Property, Plant and Equipment (Tables)              HTML     64K 
63: R47         Leases (Tables)                                     HTML     97K 
64: R48         Indebtedness (Tables)                               HTML     71K 
65: R49         Equity (Tables)                                     HTML    140K 
66: R50         Earnings per Share (Tables)                         HTML     61K 
67: R51         Share-Based Payments (Tables)                       HTML    155K 
68: R52         Income Taxes (Tables)                               HTML    131K 
69: R53         Other Consolidated Financial Statement Detail       HTML     94K 
                (Tables)                                                         
70: R54         Collaborative and Other Relationships (Tables)      HTML    132K 
71: R55         Segment Information (Tables)                        HTML     91K 
72: R56         Summary of Significant Accounting Policies -        HTML     87K 
                Narrative (Details)                                              
73: R57         Summary of Significant Accounting Policies -        HTML     60K 
                Summary of Property, Plant and Equipment Estimated               
                Useful Lives (Details)                                           
74: R58         Acquisitions -Narrative (Details)                   HTML    116K 
75: R59         Acquisitions - Purchase Price Consideration         HTML     57K 
                (Details)                                                        
76: R60         Acquisitions Preliminary Purchase Price Allocation  HTML    116K 
                (Details)                                                        
77: R61         Dispositions (Details)                              HTML     96K 
78: R62         Restructuring - Narrative (Details)                 HTML     64K 
79: R63         Restructuring, Business Transformation and Other    HTML     66K 
                Cost Saving Initiatives - Fit for Growth                         
                Initiative (Details)                                             
80: R64         Restructuring, Business Transformation and Other    HTML     67K 
                Cost Saving Initiatives - Total Charges cost                     
                saving initiative (Details)                                      
81: R65         Restructuring - Restructuring Reserve Roll Forward  HTML     58K 
                (Details)                                                        
82: R66         Revenue - Revenues by Product (Details)             HTML    144K 
83: R67         Revenue - Narrative (Details)                       HTML     74K 
84: R68         Revenue - Reserves for Discounts and Allowances     HTML     69K 
                (Details)                                                        
85: R69         Revenue - Total Reserves for Discounts and          HTML     54K 
                Allowances (Details)                                             
86: R70         Revenue - Revenues from Anti-CD20 Therapeutic       HTML     66K 
                Programs (Details)                                               
87: R71         Revenue - Other Revenues (Details)                  HTML     62K 
88: R72         Inventory - Components of Inventory (Details)       HTML     63K 
89: R73         Inventory - Narrative (Details)                     HTML     64K 
90: R74         Intangible Assets and Goodwill - Summary of         HTML     85K 
                Intangible Assets (Details)                                      
91: R75         Intangible Assets and Goodwill - Narrative          HTML    128K 
                (Details)                                                        
92: R76         Intangible Assets and Goodwill - Estimated Future   HTML     56K 
                Amortization of Intangible Assets (Details)                      
93: R77         Intangible Assets and Goodwill - Changes in         HTML     53K 
                Goodwill (Details)                                               
94: R78         Fair Value Measurements - Summary of Assets and     HTML    114K 
                Liabilities Recorded at Fair Value (Details)                     
95: R79         Fair Value Measurements - Narrative (Details)       HTML     84K 
96: R80         Fair Value Measurements - Fair Value of Contingent  HTML     53K 
                Consideration Obligations (Details)                              
97: R81         Fair Value Measurements - Summary of Fair and       HTML     91K 
                Carrying Value of Debt Instruments (Details)                     
98: R82         Financial Instruments - Summary of Financial        HTML     56K 
                Assets with Maturities (Details)                                 
99: R83         Financial Instruments - Summary of Marketable       HTML     90K 
                Securities (Details)                                             
100: R84         Financial Instruments - Summary of Contractual      HTML     66K  
                Maturities (Details)                                             
101: R85         Financial Instruments - Narrative (Details)         HTML     50K  
102: R86         Financial Instruments - Proceeds from Marketable    HTML     52K  
                Debt Securities (Details)                                        
103: R87         Derivative Instruments - Narrative (Details)        HTML     82K  
104: R88         Derivative Instruments - Foreign Currency Forward   HTML     56K  
                Contracts Entered into Hedge Forecasted Revenues                 
                (Details)                                                        
105: R89         Derivative Instruments - Summary of Unrealized      HTML     54K  
                Gain (Loss) on Derivative Instruments Included in                
                AOCI (Details)                                                   
106: R90         Derivative Instruments - Summary of the Effect of   HTML     56K  
                Derivatives Designated as Cash Flow Hedging                      
                Instruments (Details)                                            
107: R91         Derivative Instruments - Summary of the Effect of   HTML     62K  
                Derivatives Designated as Net Investment Hedging                 
                Instruments (Details)                                            
108: R92         Derivative Instruments - Summary of the Fair Value  HTML     60K  
                for our Outstanding Derivatives (Details)                        
109: R93         Property, Plant and Equipment - Components of       HTML     78K  
                property, plant, and equipment, net (Details)                    
110: R94         Property, Plant and Equipment - Narrative           HTML     91K  
                (Details)                                                        
111: R95         Leases - Narrative (Details)                        HTML     82K  
112: R96         Leases - Schedule of Operating Leases (Details)     HTML     59K  
113: R97         Leases - Operating Lease Costs (Details)            HTML     58K  
114: R98         Leases - Operating Lease Liability Maturity         HTML     64K  
                (Details)                                                        
115: R99         Leases - Operating Lease Weighted Average           HTML     49K  
                Remaining Term and Discount Rate (Details)                       
116: R100        Leases - Operating Lease Supplemental Cash Flow     HTML     49K  
                Disclosure (Details)                                             
117: R101        Indebtedness - Summary of Indebtedness (Details)    HTML     84K  
118: R102        Indebtedness - Narrative (Details)                  HTML    149K  
119: R103        Indebtedness - Total Debt Maturities (Details)      HTML     71K  
120: R104        Equity - Narrative (Details)                        HTML     77K  
121: R105        Equity - Summary of Common Stock (Details)          HTML     53K  
122: R106        Equity - Accumulated Other Comprehensive Income     HTML     95K  
                (Loss) (Details)                                                 
123: R107        Equity - Reclassification out of Accumulated Other  HTML     95K  
                Comprehensive Income (Details)                                   
124: R108        Earnings per Share - Basic and Diluted Earnings     HTML     78K  
                Per Share (Details)                                              
125: R109        Earnings per Share - Narrative (Details)            HTML     50K  
126: R110        Share-Based Payments - Share-based Compensation     HTML     63K  
                Expense Included in Consolidation Statements of                  
                Income (Details)                                                 
127: R111        Share-Based Payments - Summary of Share-based       HTML     70K  
                Compensation Expense Associated with Each                        
                Share-based Compensating Programs (Details)                      
128: R112        Share-Based Payments - Narrative (Details)          HTML    144K  
129: R113        Share-Based Payments - Employee Stock Options       HTML     79K  
                (Details)                                                        
130: R114        Share-Based Payments - Market Stock Units Activity  HTML     70K  
                (Details)                                                        
131: R115        Share-Based Payments - Assumptions Used in          HTML     73K  
                Valuation of Market Based Stock Units (Details)                  
132: R116        Share-Based Payments - Performance Stock Units      HTML     70K  
                Settled in Stock Activity (Details)                              
133: R117        Share-Based Payments - Assumptions Used in          HTML     73K  
                Valuation of Performance Shares (Details)                        
134: R118        Share-Based Payments - Performance Stock Units      HTML     59K  
                Settled in Cash Activity (Details)                               
135: R119        Share-Based Payments - Time-Vested Restricted       HTML     74K  
                Stock Units Activity (Details)                                   
136: R120        Share-Based Payments - Shares Issued Under          HTML     54K  
                Employee Stock Purchase Plan (Details)                           
137: R121        Income Taxes - Income Before Income Tax Provision   HTML     84K  
                and the Income Tax Expense (Details)                             
138: R122        Income Taxes - Narrative (Details)                  HTML    107K  
139: R123        Income Taxes - Components of Deferred Tax Assets    HTML     82K  
                and Liabilities (Details)                                        
140: R124        Income Taxes - Tax Rate (Details)                   HTML     73K  
141: R125        Income Taxes - Accounting for Uncertainty in        HTML     59K  
                Income Taxes (Details)                                           
142: R126        Other Consolidated Financial Statement Detail -     HTML     50K  
                Supplemental Cash Flow Information (Details)                     
143: R127        Other Consolidated Financial Statement Detail -     HTML     71K  
                Other Income (Expense), Net (Details)                            
144: R128        Other Consolidated Financial Statement Detail -     HTML     61K  
                Narrative (Details)                                              
145: R129        Other Consolidated Financial Statement Detail -     HTML     52K  
                Gain (Loss) on Investments (Details)                             
146: R130        Other Consolidated Financial Statement Detail -     HTML     64K  
                Accrued Expense and Other (Details)                              
147: R131        Collaborative and Other Relationships - OCREVUS     HTML     59K  
                (Details)                                                        
148: R132        Collaborative and Other Relationships -             HTML     57K  
                Mosunetuzumab (Details)                                          
149: R133        Collaborative and Other Relationships -             HTML     52K  
                Co-promotion Profit Sharing Formula (Details)                    
150: R134        Collaborative and Other Relationships - Profit      HTML     65K  
                Sharing (Details)                                                
151: R135        Collaborative and Other Relationships - Pretax      HTML     51K  
                Profit Sharing Formula (Details)                                 
152: R136        Collaborative and Other Relationships - Revenues    HTML     64K  
                from Anti-CD20 Therapeutic Programs (Details)                    
153: R137        Collaborative and Other Relationships - Ionis       HTML    113K  
                (Details)                                                        
154: R138        Collaborative and Other Relationships - Eisai       HTML     62K  
                (Details)                                                        
155: R139        Collaborative and Other Relationships - Summary of  HTML     56K  
                Activity Related to BAN2401 and Elenbecestat                     
                Collaboration (Details)                                          
156: R140        Collaborative and Other Relationships - ADUHELM     HTML     86K  
                Collaboration Agreement (Details)                                
157: R141        Collaborative and Other Relationships - Summary of  HTML     63K  
                Activity Related to Aducanumab Collaboration                     
                (Details)                                                        
158: R142        Collaborative and Other Relationships - Summary of  HTML     51K  
                Activity Related to the UCB Collaboration                        
                (Details)                                                        
159: R143        Collaborative and Other Relationships - Alkermes    HTML     55K  
                (Details)                                                        
160: R144        Collaborative and Other Relationships - Acorda      HTML     49K  
                (Details)                                                        
161: R145        Collaborative and Other Relationships - Other       HTML     85K  
                Arrangements (Details)                                           
162: R146        Collaborative and Other Relationships - Summary of  HTML     55K  
                Activity Related to Sage Therapeutics (Details)                  
163: R147        Collaborative and Other Relationships - Summary of  HTML     51K  
                Activity Related To Denali Therapeutics (Details)                
164: R148        Collaborative and Other Relationships - Summary of  HTML     51K  
                Activity Related to Sangamo Therapeutics (Details)               
165: R149        Collaborative and Other Relationships - Samsung     HTML    146K  
                Bioepis (Details)                                                
166: R150        Investments in Variable Interest Entities           HTML     79K  
                (Details)                                                        
167: R151        Litigation (Details)                                HTML     64K  
168: R152        Commitments and Contingencies (Details)             HTML    111K  
169: R153        Employee Benefit Plans (Details)                    HTML     73K  
170: R154        Segment Information - Narrative (Details)           HTML     52K  
171: R155        Segment Information - Geographic Information        HTML     90K  
                (Details)                                                        
173: XML         IDEA XML File -- Filing Summary                      XML    336K  
176: XML         XBRL Instance -- biib-20231231_htm                   XML   5.47M  
172: EXCEL       IDEA Workbook of Financial Report Info              XLSX    408K  
13: EX-101.CAL  XBRL Calculations -- biib-20231231_cal               XML    381K 
14: EX-101.DEF  XBRL Definitions -- biib-20231231_def                XML   2.21M 
15: EX-101.LAB  XBRL Labels -- biib-20231231_lab                     XML   3.89M 
16: EX-101.PRE  XBRL Presentations -- biib-20231231_pre              XML   2.94M 
12: EX-101.SCH  XBRL Schema -- biib-20231231                         XSD    451K 
174: JSON        XBRL Instance as JSON Data -- MetaLinks              968±  1.49M  
175: ZIP         XBRL Zipped Folder -- 0000875045-24-000009-xbrl      Zip   2.28M  

‘XML’   —   XBRL Instance — biib-20231231_htm

This Document is an XBRL File.